Today: 21 May 2026
Browse Category

NYSE:JNJ 13 December 2025 - 24 December 2025

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson traded near $207 per share in thin holiday trading Wednesday, keeping its market value around $500 billion. A Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest such verdict to date. J&J said it will appeal. U.S. markets close early at 1 p.m. ET for Christmas Eve.
24 December 2025
···
Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson shares fell 0.9% to $205.43 on Dec. 23 after a Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest single-plaintiff award in this litigation. J&J plans to appeal and maintains its talc products are safe. The company faces more than 67,000 talc-related lawsuits. Broader U.S. indexes closed modestly higher.
23 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

A Baltimore jury ordered Johnson & Johnson and spinoff Kenvue to pay over $1.5 billion in a talc cancer case, with J&J saying it will appeal. Kenvue shares traded at $16.98, about $1.15 below the implied $18.12 merger value based on Kimberly-Clark’s price, reflecting deal risk. The acquisition is expected to close in the second half of 2026. J&J has said it will cover Kenvue’s talc liabilities.
23 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson closed Monday at $207.32, up 0.46%, with after-hours trading showing little movement on light volume. Investors tracked Washington’s drug-pricing push and new talc-litigation updates. Hedge funds turned more cautious on healthcare stocks, according to Reuters. NYSE will close early Wednesday and remain shut Thursday for Christmas.
23 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson shares traded at $206.63 Monday after the European Commission approved TREMFYA for pediatric psoriasis, marking its first IL-23 inhibitor indication in children. The company also secured recent FDA approvals for RYBREVANT FASPRO in lung cancer and TRUFILL n-BCA for chronic subdural hematoma. Ongoing talc litigation continues to affect investor sentiment.
22 December 2025
·
Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson shares closed at $206.37 on Friday, about 4% below their 52-week high. A Minnesota jury awarded $65.5 million in a talc cancer case against the company, which plans to appeal. The FDA granted a priority review voucher for J&J’s Tecvayli-Darzalex multiple myeloma regimen, speeding regulatory timelines. Trading may see sharper moves this week due to holiday liquidity.
22 December 2025
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson closed Friday, Dec. 19, 2025, at about $206 per share, as investors weighed U.S. drug-pricing negotiations and new talc verdicts against product pipeline momentum. The company is set to meet with the White House after the holidays over possible participation in the TrumpRx drug-pricing initiative. Trading volume is expected to be thin during the Christmas-shortened week.
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

A Minnesota jury awarded $65.5 million to a plaintiff who said Johnson & Johnson’s talc products caused mesothelioma, with J&J vowing to appeal. JNJ shares last traded at $206.37, down 0.9% from the prior close and about 3.6% below their December 15 record. Over 67,000 plaintiffs are suing J&J over similar claims. The company declared a $1.30 quarterly dividend for Q4 2025.
20 December 2025
·
Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson shares rose 0.51% to $207.43 in after-hours trading Friday, after closing down 0.9% in the regular session. The move followed late news on Washington drug-pricing talks, analyst targets, and litigation. JNJ was not among nine firms signing new Trump administration drug-pricing deals but was named as a company in ongoing discussions. U.S. markets are closed Saturday; trading resumes Monday.
20 December 2025
·
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson shares hovered near $208 intraday on December 19, 2025, as investors weighed new U.S. drug-pricing talks involving the company, recent FDA approvals, and ongoing talc litigation. Reuters reported J&J remains in negotiations with the White House over prescription drug pricing reforms. The FDA approved Rybrevant Faspro for subcutaneous use in EGFR-mutated NSCLC.
19 December 2025
·
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson shares closed Thursday at $208.31, down 0.96%, then edged up to $208.65 after hours. The company announced FDA clearance expanding TRUFILL n‑BCA’s use for chronic subdural hematoma and FDA approval for RYBREVANT FASPRO as a subcutaneous lung cancer treatment. JNJ’s market cap stands near $502 billion.
19 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson shares traded near $210 on December 17, 2025, after a sharp drop the previous day and renewed analyst attention. RBC raised its price target to $240, maintaining an Outperform rating. The stock remains close to 2025 highs, with analysts split on near-term upside. JNJ continues to offer a quarterly dividend of $1.30 per share, yielding around 2%.
17 December 2025
·
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson shares fell about 1% to $211–$212 late Tuesday morning after hitting recent highs, following news that the FDA granted a National Priority Voucher for its Tecvayli and Darzalex combination therapy for multiple myeloma. The FDA highlighted strong Phase 3 results and rapid review plans. Investors await the company’s upcoming earnings update for further guidance.
16 December 2025
···
Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson shares closed up 1.22% at $214.17 Monday and traded higher after hours following news that the FDA awarded a national priority voucher for its Tecvayli-daratumumab combination in relapsed/refractory multiple myeloma. The voucher, tied to strong Phase 3 MajesTEC-3 results, allows for accelerated FDA review. U.S. stocks overall ended slightly lower ahead of key economic data releases.
16 December 2025
·
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson shares closed at $211.58 on Dec. 12, 2025, up 4.9% for the week after an FDA approval for AKEEGA in prostate cancer and new multiple myeloma data. The stock outperformed the broader market despite renewed talc litigation risk. A Federal Reserve rate cut earlier in the week supported large healthcare stocks. JNJ traded as high as $212.27 intraday Friday.
13 December 2025
··
1 … 4 5 6 7 8

Stock Market Today

  • Planet Labs Nears Sustainable Profitability Amid Industry Challenges
    May 21, 2026, 3:12 PM EDT. Planet Labs (PL) operates a vast network of Earth observation satellites capturing global images daily. Despite technological advances and expanded roles in defense and agriculture, the company has yet to secure steady profits due to high costs in satellite manufacturing, launches, maintenance, and R&D. Revenue growth lags behind fixed costs, while long government sales cycles delay cash flow. Management's 2026 guidance shows optimism, focusing on cost control, vertical specialization, and software monetization to enhance margins. Industry peers Rocket Lab (RKLB) and BlackSky Technology (BKSY) face similar profitability challenges. PL's stock has surged 117% year-to-date but trades at a lofty price-to-sales ratio of 31.38, far above the industry average of 3.86, reflecting high investor expectations amid ongoing financial pressures.

Latest articles

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

21 May 2026
Nebius Group N.V. shares surged 15.6% to $221.72 after announcing a fuel cell power deal with Bloom Energy, securing up to 328 MW of on-site electricity capacity for its AI infrastructure. The agreement could cost Nebius up to $2.6 billion over 10 years. Bloom shares rose 12.2% on the news. Nebius's first-quarter revenue jumped to $399 million from $50.9 million a year earlier.
Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
Go toTop